5 million in disability benefits is unclaimed by people identified as having terminal cancer in the UK. Literally a large number of cancer patients are not claiming benefits to that they are entitled. Whether that is due to lack of information, confusion or embarrassment, it highlights the need for better individual education in the U Ranbaxy Laboratories LTD .K. Related StoriesPatients knowledge improvements in joint specific discomfort and function after weight-reduction surgeryMinimally invasive implant procedure effective for patients with sacroiliac joint dysfunctionResearchers recognize potential brain-structured biomarker for depressive symptomsOther crucial highlights of the unclaimed millions are that: More than half of individuals with cancer who die each year usually do not claim their entitled disability benefits.
Both the full study-entry criteria, contained in the Supplementary Appendix, and the trial protocol are available with the full text of this article at NEJM.org.25 Patients with either newly diagnosed or relapsing disease were qualified to receive enrollment. The RAVE trial was approved by the institutional evaluate panel at each participating site. All sufferers provided written informed consent. Patients were assigned randomly, in a 1:1 ratio, to investigational therapy or regular therapy . Randomization was stratified according to clinical ANCA and site type. Treatments The remission-induction period was 6 months. Patients in the control group who had a remission between 3 and six months were eligible to switch from cyclophosphamide to azathioprine . The two treatment groups received the same glucocorticoid regimen: someone to three pulses of methylprednisolone , accompanied by prednisone at a dose of 1 1 mg per kilogram per day.